M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn Pharmaceutical TechnologyGilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) Pharmaceutical Technology Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Read full story Post navigation Previous: In Alzheimer’s, Bristol Myers sees big promise beyond amyloidNext: GBL joins CVC in 10.7bn takeover bid for Recordati Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
